Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuna Mutis

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Blood Cancer Journal|October 6, 2025
Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCLHilma J van der Horst, Tamás Csikós, Marjolein Quik, et al.
Haematologica|February 10, 2016
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaEsther Drent, Richard W J Groen, Willy A Noort, et al.
Blood Advances|October 9, 2021
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myelomaKristine A Frerichs, Monique C Minnema, Mark-David Levin, et al.
Blood Cancer Journal|February 19, 2021
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatmentHilma J van der Horst, A Vera de Jonge, Ida H Hiemstra, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2003
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemiaW A Erik Marijt, Mirjam H M Heemskerk, Freke M Kloosterboer, et al.
Hemasphere|November 15, 2024
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myelomaWassilis S C Bruins, Rosa Rentenaar, John Newcomb, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 12, 2018
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of ActionHomer C Adams, Frederik Stevenaert, Jakub Krejcik, et al.
Blood Advances|April 23, 2021
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myelomaChristie P M Verkleij, Marloes E C Broekmans, Mark van Duin, et al.
Blood|June 17, 2016
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaInger S Nijhof, Tineke Casneuf, Jeroen van Velzen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by DaratumumabKristine A Frerichs, Marloes E C Broekmans, Jhon A Marin Soto, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Blood Cancer Journal|October 6, 2025
Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCLHilma J van der Horst, Tamás Csikós, Marjolein Quik, et al.
Haematologica|February 10, 2016
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaEsther Drent, Richard W J Groen, Willy A Noort, et al.
Blood Advances|October 9, 2021
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myelomaKristine A Frerichs, Monique C Minnema, Mark-David Levin, et al.
Blood Cancer Journal|February 19, 2021
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatmentHilma J van der Horst, A Vera de Jonge, Ida H Hiemstra, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 26, 2003
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemiaW A Erik Marijt, Mirjam H M Heemskerk, Freke M Kloosterboer, et al.
Hemasphere|November 15, 2024
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myelomaWassilis S C Bruins, Rosa Rentenaar, John Newcomb, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 12, 2018
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of ActionHomer C Adams, Frederik Stevenaert, Jakub Krejcik, et al.
Blood Advances|April 23, 2021
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myelomaChristie P M Verkleij, Marloes E C Broekmans, Mark van Duin, et al.
Blood|June 17, 2016
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaInger S Nijhof, Tineke Casneuf, Jeroen van Velzen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by DaratumumabKristine A Frerichs, Marloes E C Broekmans, Jhon A Marin Soto, et al.
Pageof 11